Cognex vs Ralliant
CGNX and RAL side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGNX and RAL compare
Cognex and Ralliant are about the same size, with market caps of $8.4B and $7.6B.
Cognex grew revenue faster over the last twelve months (15.8% versus 10.4% for Ralliant).
Cognex keeps more of each dollar of sales as profit, with a net margin of 21.5% compared with −52.1% at Ralliant.
Both pay dividends: Cognex yields 0.51% and Ralliant 0.29%.
Cognex scores higher on the StockData Score (20 against 7 for Ralliant), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGNX | RAL |
|---|---|---|
| Size and price | ||
| Market cap | $8.4B | $7.6B |
| Share price | $50.01 | $68.73 |
| Change, 1 year | 31.0% | 43.8% |
| Change, 5 years | −37.5% | – |
| Beta (5Y) | 1.30 | 0.86 |
| Employees | 2,267 | 7,000 |
| StockData Score | ||
| Total score | 20 (better) | 7 |
| Valuation score | 4 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 4 (better) | 0 |
| Health score | 6 (better) | 2 |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/E | 35.0× | – |
| P/S | 7.5× | 3.3× (better) |
| P/B | 4.9× | 4.7× (better) |
| EV/EBITDA | 27.4× | – |
| P/FCF | 29.4× | 25.1× (better) |
| FCF yield | 3.4% | 4.0% (better) |
| Fair value | $57.10 | $51.93 |
| Margin of safety | 12.4% (better) | −32.3% |
| Growth | ||
| Revenue growth (TTM) | 15.8% (better) | 10.4% |
| Revenue growth, 5Y average | 4.2% | – |
| Net income growth (TTM) | 120% (better) | −607% |
| EPS growth (TTM) | 123% (better) | −615% |
| EPS growth, 5Y average | −7.4% | – |
| Profitability | ||
| Gross margin | 69.7% (better) | 51.6% |
| Operating margin | 25.0% (better) | −48.3% |
| Net margin | 21.5% (better) | −52.1% |
| FCF margin | 25.4% (better) | 13.3% |
| Return on equity | 15.1% (better) | −51.8% |
| Return on invested capital | 20.6% (better) | −27.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.71 (better) |
| Interest coverage | – | −19.0× |
| Current ratio | 5.04 (better) | 1.65 |
| Altman Z-score | 10.77 (better) | 1.43 |
| Piotroski F-score | 8 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.51% (better) | 0.29% |
| Payout ratio | 23.5% | – |
| Years of dividend growth | 4 (better) | 0 |
| Dividend growth, 5Y average | −31.9% | – |
| Buyback yield | 1.5% | – |
| Shareholder yield | 2.1% (better) | 0.29% |
| Ownership | ||
| Held by institutions | 104% | 102% |
| Held by insiders | 0.38% | 0.51% |
| Insider net buying, 12 months | −$34.8M | −$4.7M (better) |
| Short interest, % of float | 3.9% | 4.3% |
Go deeper
- CGNX stock overview
- CGNX income statement
- CGNX valuation and score
- RAL stock overview
- RAL income statement
- RAL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.